Naresh Patel, MD
Cardiovascular Disease · Fort Worth, TXNPI 1801885769
Payments from drug & device makers
Across 193 payments — averaging $21.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$716
- AstraZeneca$414
- Biotronik Inc.$318
- Johnson & Johnson$311
- Pfizer$306
- Amarin Pharma, Inc.$280
- plus $2K from 23 others
Across 1 payment — averaging $226.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Nevro Corp.$227
What the payments were for
- Food & beverage$3,97394%
- Education$2376%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 36 | $716 |
| AstraZeneca | 16 | $414 |
| Biotronik Inc. | 5 | $318 |
| Johnson & Johnson | 25 | $311 |
| Pfizer | 14 | $306 |
| Amarin Pharma, Inc. | 13 | $280 |
| Abbott | 9 | $254 |
| Heartflow, Inc. | 2 | $196 |
| Edwards Lifesciences | 3 | $156 |
| Bayer | 8 | $146 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $145 |
| Amgen | 9 | $128 |
| Boehringer Ingelheim | 6 | $111 |
| Impulse Dynamics (USA) Inc. | 4 | $104 |
| Merck | 6 | $101 |
| Sanofi-aventis U.S. LLC | 5 | $86 |
| E.r. Squibb & Sons, L.L.C. | 4 | $84 |
| Atricure, Inc. | 1 | $54 |
| Boston Scientific | 3 | $50 |
| Novo Nordisk | 2 | $47 |
| Tactile Systems Technology Inc | 2 | $47 |
| Cardiovascular Systems Inc. | 2 | $36 |
| Bardy Diagnostics, Inc. | 2 | $22 |
| Cook Medical LLC | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| Medtronic | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Getinge USA Sales, LLC | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orsiro Mission$251
- FFRct$132
- Edwards SAPIEN 3 Transcatheter Heart Valve$130
- Vascepa$125
- VYNDAQEL$115
How this compares
$4,211 in reported general payments places this provider in the 50th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 28 | $449 |
| Rosuvastatin Calcium | 23 | $392 |
| Atorvastatin Calcium | 16 | $99 |
| Carvedilol | 13 | $51 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Fort Worth
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.